New Jersey, USA-based Lux Biosciences, a privately-held biotechnology company specialized in the field of ophthalmic diseases, has announced the closing of a $36.0 million series A financing.
The financing included equal participation of funds managed by HBM Partners AG, Novo A/S and SV Life Sciences. As part of the transaction, Axel Bolte, investment advisor at HBM Partners, Thomas Dyrberg, a partner at Novo, and Lutz Giebel, general partner at SV Life Sciences, will join the Lux Biosciences board.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze